Evidence map›Paper›PMID 32227276›Full record

ArticleWorld journal of surgery2020

Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules.

L Ravella, J Lopez, F Descotes, J Giai, V Lapras, M-L Denier, F Borson-Chazot, J-C Lifante, M Decaussin-Petrucci

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Diagnostic value ofFrontiers in oncology · 2025
    Pooled it
  2. Article
  3. Comparing Diagnostic Accuracy of BRAF Marker with Surgery Findings in Detecting the Type of Lesion in Patients with Thyroid Nodules with Suspected Fine Needle Aspiration (AUS).Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025
    Article
  4. Review
  5. Diagnostic utility ofEXCLI journal · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

L RavellaPathology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
J LopezBiochemistry and Molecular Biology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
F DescotesBiochemistry and Molecular Biology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
J GiaiCNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, 69622, Villeurbanne, France.
V LaprasRadiology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
M-L DenierRadiology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
F Borson-ChazotEndocrinology Department, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.
J-C LifanteEndocrine Surgery Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
M Decaussin-PetrucciPathology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France. myriam.decaussin-petrucci@chu-lyon.fr.
Hôpital Lyon Sud · FRHospices Civils de Lyon · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRAS and K601E BRAF mutations are not a reliable indicator of malignancy in fine-needle aspirations (FNA) of thyroid indeterminate cytologic nodules. We aimed to evaluate the histologic characteristics, the risk of malignancy associated with such mutations in FNA and their potential interest for preoperative clinical management of nodules.

methodsWe evaluated 69 indeterminate thyroid nodules with RAS or K601E BRAF mutations with available histopathologic follow-up. All FNA specimens were indeterminate according to the thyroid Bethesda system. Diagnosis of malignant, benign or indolent neoplasms was classified according to 2017 WHO classification. Carcinoma, NIFTP (noninvasive follicular thyroid neoplasm with papillary-like features) and WDTUMP (well-differentiated tumor of uncertain malignant potential) were considered "surgical," as they require surgical excision. Adenoma was considered "non-surgical." The risk of malignancy and the risk of "surgical disease" were evaluated.

resultsPathologic evaluation of the 69 mutated nodules demonstrated benign, indolent and malignant histology in 17 cases (25%), 21 cases (30%) and 31 cases (45%), respectively. The risk of malignancy was 45%, and the risk of surgical disease was 75%. The majority of carcinomas were a follicular variant of papillary thyroid carcinoma. On follow-up, there have been no recurrences to date.

conclusionPreoperative RAS or BRAF K601E mutations detection in cytologic indeterminate thyroid nodules carries a high risk of surgical disease and may benefit from surgical management. Most surgical lesions harboring those mutations are low-risk tumors, which may be in favor of an initial lobectomy.

Indexed as

ThyroidectomyAdenocarcinoma, FollicularAdultAgedBiomarkers, TumorBiopsy, Fine-NeedleClinical Decision-MakingFemaleFollow-Up StudiesGenetic TestingGTP PhosphohydrolasesHumansMaleMembrane ProteinsMiddle AgedMutationBiomarkers, TumorBRAF protein, humanGTP PhosphohydrolasesHRAS protein, humanMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)

Identifiers

PMID32227276
OpenAlexW3013918070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.